## Edgar Filing: NOVADEL PHARMA INC - Form 4

NOVADEL Form 4 January 26,	PHARMA INC 2009									
FORM	ΠД								PPROVAL	
	UNITED	STATES		RITIES A			E COMMISSION	N OMB Number:	3235-0287	
Check th if no lon subject t Section Form 4 of Form 5 obligation may con <i>See</i> Instr 1(b).	ger o 16. or Filed pu nns tinue. Section 17	box <b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940							irs per	
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> ZODDA DENI M PHD			2. Issuer Name <b>and</b> Ticker or Trading Symbol NOVADEL PHARMA INC [NVD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First)	(Middle)	3. Date of	of Earliest T	ransaction		(Che	ск ан аррисаы	e)	
			(Month/Day/Year) 01/22/2009			Director       10% Owner         X Officer (give title Other (specify below)         SVP and Chief Business Officer				
				iled(Month/Day/Year) Applicable I			Applicable Line)	or Joint/Group Filing(Check e) by One Reporting Person		
FLEMING	TON, NJ 08822							More than One R		
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		C 1 1	C	Code V		(D) Price	· 1· 4			
Keminder: Rej	port on a separate lin	le for each cl	ass of sec	urities benei	Perso	ons who res	or indirectly. spond to the colle tained in this form		SEC 1474 (9-02)	

Persons who respond to the collection of SEC 147 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: NOVADEL PHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	/ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.34	01/22/2009		А	125,000		<u>(1)</u>	01/22/2014	Common Stock, \$0.001 par value	125,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
ZODDA DENI M PHD C/O NOVADEL PHARMA INC. 25 MINNEAKONING ROAD FLEMINGTON, NJ 08822			SVP and Chief Business Officer				
Signatures							

/s/ Deni M. Zodda, Ph.D.	01/26/2009		
<u>**</u> Signature of Reporting Person	Date		

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person received options to purchase 125,000 shares of common stock, which become exercisable in equal monthly (1) installments over a period of twenty-four months.
- (2) Includes multiple option grants and vesting schedules.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.